Herpes simplex and varicella zoster viruses: Forgotten but not gone

American Journal of Transplantation

Volumn 7, Issue 4, 2007, Pages 741-747

  Miller, G G ^a   Dummer, J S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Herpes simplex; Immunosuppression; Transplantation; Varicella zoster

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CHICKENPOX VACCINE; CYCLOSPORIN A; FAMCICLOVIR; GANCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE;

ANTIBODY RESPONSE; CANADA; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; DRUG WITHDRAWAL; GENITAL HERPES; GRAFT RECIPIENT; HEART TRANSPLANTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; IMMEDIATE EARLY GENE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; SEROPREVALENCE; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS LATENCY; VIRUS REACTIVATION;

HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INCIDENCE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SIMPLEXVIRUS;

EID: 33947598052     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01718.x     Document Type: Short Survey

References (71)

1. da Silva LM, Guimaraes AL, Victoria JM, Gomes CC, Gomez RS. Herpes simplex virus type 1 shedding in the oral cavity of seropositive patients. Oral Dis 2005; 11: 13-16.
2. Koelle DM, Wald A. Herpes simplex virus: The importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45(Suppl T3): 1-8.
3. Mitchell BM, Bloom DC, Cohrs RJ, Gilden DH, Kennedy PG. Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J Neurovirol 2003; 9: 194-204.
4. Efstathiou S, Preston CM. Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res 2005; 111: 108-119.
5. Feldman LT, Ellison AR, Voytek CC et al. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 2002; 99: 978-983.
6. Halford WP, Weisend C, Grace J et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: Implications for the regulation of viral latency. Virol J 2006; 3: 44.
7. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Dermatol Surg 2000; 26: 50-54.
8. Tenser RB. Trigeminal neuralgia: Mechanisms of treatment. Neurology 1998; 51: 17-19.
9. Bruynseels P, Jorens PG, Demey HE et al. Herpes simplex virus in the respiratory tract of critical care patients: A prospective study. Lancet 2003; 362: 1536-1541.
10. Theil D, Derfuss T, Paripovic I et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003; 163: 2179-2184.
11. + CTL in persons with frequently recurring genital herpes. J Immunol 2000; 165: 1146-1152.
12. Khanna KM, Lepisto AJ, Decman V, Hendricks RL. Immune control of herpes simplex virus during latency. Curr Opin Immunol 2004; 16: 463-469.
13. Braun RP, Payne LG, Dong L. Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes. Virol J 2006; 3: 54.
14. Gnann JW Jr. Herpes simplex and varicella zoster virus infection after hemopoietic stem cell or solid organ transplantation. In: Bowden R, Lungman P, Paya CV, eds. Transplant infections. Philadelphia: Lippincott, Williams, and Wilkins, 2004: 350-366.
15. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86-124.
16. Singh N, Dummer JS, Kusne S et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124-131.
17. Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977; 136: 531-540.
18. Smyth RL, Higenbottam TW, Scott JP et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990; 49: 735-739.
19. Schillinger JA, Xu F, Sternberg MR et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004; 31: 753-760.
20. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337: 1105-1111.
21. Scott JP, Fradet G, Smyth RL et al. Management following heart and lung transplantation: Five years experience. Eur J Cardiothorac Surg 1990; 4: 197-200.
22. Singhal S, Muir DA, Ratcliffe DA et al. Respiratory viruses in adult liver transplant recipients. Transplantation 1999; 68: 981-984.
23. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983; 36: 259-267.
24. Kusne S, Dummer JS, Singh N et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67: 132-143.
25. Kusne S, Schwartz M, Breinig MK et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163: 1001-1007.
26. Elliott WC, Houghton DC, Bryant RE et al. Herpes simplex type 1 hepatitis in renal transplantation. Arch Intern Med 1980; 140: 1656-1660.
27. Taylor RJ, Saul SH, Dowling JN et al. Primary disseminated herpes simplex infection with fulminant hepatitis following renal transplantation. Arch Intern Med 1981; 141: 1519-1521.
28. Dummer JS, Armstrong J, Somers J et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987; 155: 202-206.
29. Koneru B, Tzakis AG, DePuydt LE et al. Transmission of fatal herpes simplex infection through renal transplantation. Transplantation 1988; 45: 653-656.
30. Ichai P, Afonso AM, Sebagh M et al. Herpes simplex virus-associated acute liver failure: A difficult diagnosis with a poor prognosis. Liver Transpl 2005; 11: 1550-1555.
31. Campsen J, Hendrickson R, Bak T et al. Herpes simplex in a liver transplant recipient. Liver Transpl 2006; 12: 1171-1173.
32. Shreeniwas R, Schulman LL, Berkmen YM, McGregor CC, Austin JH. Opportunistic bronchopulmonary infections after lung transplantation: Clinical and radiographic findings. Radiology 1996; 200: 349-356.
33. Singh N, Gayowski T, Wagener MM, Marino IR. Pulmonary infiltrates in liver transplant recipients in the intensive care unit. Transplantation 1999; 67: 1138-1144.
34. Seale L, Jones CJ, Kathpalia S et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985; 254: 3435-3438.
35. Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia: Clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982; 97: 813-820.
36. Kusne S, Pappo O, Manez R et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995; 60: 619-621.
37. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108-115.
38. Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: A case-control study. Liver Transpl 2005; 11: 320-325.
39. Herrero JI, Quiroga J, Sangro B et al. Herpes zoster after liver transplantation: Incidence, risk factors, and complications. Liver Transpl 2004; 10: 1140-1143.
40. Cabezon RS, Cisneros JM, Lage GE et al. Characteristics and repercussion of varicella-zoster virus infection in cardiac transplant. Transplant Proc 2003; 35: 2004-2005.
41. de Jong MD, Weel JF, Schuurman T, Wertheim-van Dillen PM, Boom R. Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence. J Clin Microbiol 2000; 38: 2568-2573.
42. Mainka C, Fuss B, Geiger H, Hofelmayr H, Wolff MH. Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol 1998; 56: 91-98.
43. Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after renal transplantation. Am J Kidney Dis 2001; 37: 659-676.
44. Fehr T, Bossart W, Wahl C, Binswanger U. Disseminated varicella infection in adult renal allograft recipients: Four cases and a review of the literature. Transplantation 2002; 73: 608-611.
45. Lauzurica R, Bayes B, Frias C et al. Disseminated varicella infection in adult renal allograft recipients: Role of mycophenolate mofetil. Transplant Proc 2003; 35: 1758-1759.
46. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
47. de Jong MD, Weel JF, van Oers MH, Boom R, Wertheim-van Dillen PM. Molecular diagnosis of visceral herpes zoster. Lancet 2001; 357: 2101-2102.
48. Mourad G, Garrigue V, Squifflet JP et al. Induction versus non-induction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050-1055.
49. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517-525.
50. Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999; 68: 158-161.
51. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
52. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
53. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63-67.
54. Gluckman E, Lotsberg J, Devergie A et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983; 2: 706-708.
55. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984; 100: 823-828.
56. Pettersson E, Hovi T, Ahonen J et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985; 39: 279-281.
57. Carrier M, Pelletier GB, Cartier R, Leclerc Y, Pelletier LC. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. Can J Surg 1992; 35: 513-516.
58. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: Long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186(Suppl 1):S40-S46.
59. Reitano M, Tyring S, Lang W et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998; 178: 603-610.
60. Fife KH, Warren TJ, Ferrera RD et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81: 1321-1327.
61. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs 2004; 64: 2763-2792.
62. Wald A, Selke S, Warren T et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; 33: 529-533.
63. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988; 85: 99-101.
64. Steer CB, Szer J, Sasadeusz J et al. Varicella-zoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-664.
65. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805.
66. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000; 60: 1329-1352.
67. Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006; 142: 943-945.
68. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10: 78-82.
69. Weinberg A, Horslen SP, Kaufman SS et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6: 565-568.
70. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.
71. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: Long-term results of vaccination. Pediatrics 1997; 99: 35-39.